Quick Answer
Aardvark Therapeutics, Inc. reported Net Income of -$57.59 million for fiscal year 2025.
Aardvark Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Net Income | -$57.59M -179.7% |
-$20.59M | — |
| Diluted EPS | -$2.93 +43.1% |
-$5.15 | — |
| Total Assets | $117.18M +51.2% |
$77.51M | — |
| Cash and Equivalents | $47.05M -23.7% |
$61.64M | — |
| Stockholders Equity | $106.63M +295.1% |
-$54.64M -57.0% |
-$34.80M |
| R&D Expense | $48.94M +181.8% |
$17.36M | — |
| Operating Income | -$62.73M -175.3% |
-$22.79M | — |
| Shares Outstanding | 21.82M +436.4% |
4.07M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$16.32M | -290.1% | -13.6% |
| Diluted EPS | September 30, 2025 | -$0.75 | +28.6% | -13.6% |
| Total Assets | September 30, 2025 | $133.23M | — | -9.7% |
| Cash and Equivalents | September 30, 2025 | $39.28M | — | +51.1% |
| Stockholders Equity | September 30, 2025 | $122.38M | +365.0% | -10.6% |
| R&D Expense | September 30, 2025 | $13.74M | +237.9% | +4.5% |
| Operating Income | September 30, 2025 | -$17.70M | -247.7% | -11.7% |
| Shares Outstanding | September 30, 2025 | 21.75M | — | +0.2% |
- Aardvark Therapeutics, Inc. reported Net Income of -$57.59 million for fiscal year 2025.
- Aardvark Therapeutics, Inc. showed a decrease of -179.7% in Net Income compared to the prior fiscal year.
- Aardvark Therapeutics, Inc. reported Diluted EPS of $2.93 per share (loss) for fiscal year 2025.
- Aardvark Therapeutics, Inc. showed an increase of +43.1% in Diluted EPS compared to the prior fiscal year.
- Aardvark Therapeutics, Inc. reported Total Assets of $117.18 million for fiscal year 2025.
- Aardvark Therapeutics, Inc. showed an increase of +51.2% in Total Assets compared to the prior fiscal year.
- Aardvark Therapeutics, Inc. reported Cash and Equivalents of $47.05 million for fiscal year 2025.
- Aardvark Therapeutics, Inc. showed a decrease of -23.7% in Cash and Equivalents compared to the prior fiscal year.
- Aardvark Therapeutics, Inc. reported Stockholders Equity of $106.63 million for fiscal year 2025.
- Aardvark Therapeutics, Inc. showed an increase of +295.1% in Stockholders Equity compared to the prior fiscal year.
- Aardvark Therapeutics, Inc. reported R&D Expense of $48.94 million for fiscal year 2025.
- Aardvark Therapeutics, Inc. showed an increase of +181.8% in R&D Expense compared to the prior fiscal year.
- Aardvark Therapeutics, Inc. reported Operating Income of -$62.73 million for fiscal year 2025.
- Aardvark Therapeutics, Inc. showed a decrease of -175.3% in Operating Income compared to the prior fiscal year.
- Aardvark Therapeutics, Inc. reported Shares Outstanding of 21.82 million shares for fiscal year 2025.
- Aardvark Therapeutics, Inc. showed an increase of +436.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: